APOBEC3G: An intracellular centurion

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 364, Issue 1517, 2009, Pages 689-703

  Chiu, Ya Lin ^a   Greene, Warner C ^a  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

Alu; APOBEC3G; HIV 1; Retrotransposition; RNA granules; Vif

Indexed keywords

CYTOLOGY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN; RNA; VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 60049098392     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2008.0193     Document Type: Conference Paper

References (126)

1. Abudu, A., Takaori-Kondo, A., Izumi, T., Shirakawa, K., Kobayashi, M., Sasada, A., Fukunaga, K. & Uchiyama, T. 2006 Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr. Biol. 16, 1565-1570. (doi:10.1016/j.cub.2006.06.055)
2. Alce, T. M. & Popik, W. 2004 APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279, 34 083-34 086. (doi:10.1074/jbc.C400235200)
3. Anderson, P. & Kedersha, N. 2006 RNA granules. J. Cell Biol. 172, 803-808. (doi:10.1083/jcb.200512082)
4. Beale, R. C., Petersen-Mahrt, S. K., Watt, I. N., Harris, R. S., Rada, C. & Neuberger, M. S. 2004 Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337, 585-596. (doi:10.1016/j.jmb.2004.01. 046)
5. Bishop, K. N., Holmes, R. K., Sheehy, A. M., Davidson, N. O., Cho, S. J. & Malim, M. H. 2004 Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14, 1392-1396. (doi:10.1016/j.cub.2004.06. 057)
6. Bishop, K. N., Holmes, R. K. & Malim, M. H. 2006 Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80, 8450-8458. (doi:10.1128/JVI.00839-06)
7. Bogerd, H. P., Doehle, B. P., Wiegand, H. L. & Cullen, B. R. 2004 A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl Acad. Sci. USA 101, 3770-3774. (doi:10.1073/pnas.0307713101)
8. Bogerd, H. P., Wiegand, H. L., Doehle, B. P., Lueders, K. K. & Cullen, B. R. 2006 APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 34, 89-95. (doi:10.1093/nar/gkj416)
9. Bonvin, M. et al. 2006 Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43, 1364-1374. (doi:10.1002/hep.21187)
10. Burnett, A. & Spearman, P. 2007 APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81, 5000-5013. (doi:10.1128/JVI.02237-06)
11. Cen, S., Guo, F., Niu, M., Saadatmand, J., Deflassieux, J. & Kleiman, L. 2004 The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279, 33 177-33 184. (doi:10.1074/jbc.M402062200)
12. Chelico, L., Pham, P., Calabrese, P. & Goodman, M. F. 2006 APOBEC3G DNA deaminase acts processively 3′→5′ on single-stranded DNA. Nat. Struct. Mol. Biol. 13, 392-399. (doi:10.1038/nsmb1086)
13. Chen, H., Lilley, C. E., Yu, Q., Lee, D. V., Chou, J., Narvaiza, I., Landau, N. R. & Weitzman, M. D. 2006 APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16, 480-485. (doi:10.1016/j.cub.2006.01.031)
14. Chiu, Y. L. & Greene, W. C. 2008 The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26, 317-353. (doi:10.1146/annurev.immunol.26.021607.090350)
15. Chiu, Y. L., Soros, V. B., Kreisberg, J. F., Stopak, K., Yonemoto, W. & Greene, W. C. 2005 Cellular APOBEC3G restricts HIV-1 infection in resting CD4+T cells. Nature 435, 108-114. (doi:10.1038/nature03493)
16. Chiu, Y. L., Witkowska, H. E., Hall, S. C., Santiago, M., Soros, V. B., Esnault, C., Heidmann, T. & Greene, W. C. 2006 High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl Acad. Sci. USA 103, 15 588-15 593. (doi:10.1073/pnas.0604524103)
17. Conticello, S. G., Harris, R. S. & Neuberger, M. S. 2003 The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013. (doi:10.1016/j.cub.2003.10. 034)
18. Conticello, S. G., Thomas, C. J., Petersen-Mahrt, S. K. & Neuberger, M. S. 2005 Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22, 367-377. (doi:10.1093/molbev/ msi026)
19. Dang, Y., Wang, X., Esselman, W. J. & Zheng, Y. H. 2006 Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80, 10 522-10 533. (doi:10.1128/JVI. 01123-06)
20. Delebecque, F. et al. 2006 Restriction of foamy viruses by APOBEC cytidine deaminases. J. Virol. 80, 605-614. (doi:10.1128/JVI.80.2. 605-614.2006)
21. Derse, D., Hill, S. A., Princler, G., Lloyd, P. & Heidecker, G. 2007 Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl Acad. Sci. USA 104, 2915-2920. (doi:10.1073/pnas.0609444104)
22. Dewannieux, M., Esnault, C. & Heidmann, T. 2003 LINE-mediated retrotransposition of marked Alu sequences. Nat. Genet. 35, 41-48. (doi:10.1038/ng1223)
23. Doehle, B. P., Schafer, A. & Cullen, B. R. 2005a Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339, 281-288. (doi:10.1016/j.virol.2005.06.005)
24. Doehle, B. P., Schafer, A., Wiegand, H. L., Bogerd, H. P. & Cullen, B. R. 2005b Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J. Virol. 79, 8201-8207. (doi:10.1128/JVI.79.13.8201-8207.2005)
25. Doehle, B. P., Bogerd, H. P., Wiegand, H. L., Jouvenet, N., Bieniasz, P. D., Hunter, E. & Cullen, B. R. 2006 The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. J. Virol. 80, 12 102-12 108. (doi:10.1128/JVI.01600-06)
26. Ellery, P. J. et al. 2007 The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178, 6581-6589.
27. Esnault, C., Heidmann, O., Delebecque, F., Dewannieux, M., Ribet, D., Hance, A. J., Heidmann, T. & Schwartz, O. 2005 APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433, 430-433. (doi:10.1038/nature03238)
28. Esnault, C., Millet, J., Schwartz, O. & Heidmann, T. 2006 Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 34, 1522-1531. (doi:10.1093/nar/gkl054)
29. Fabini, G., Rutjes, S. A., Zimmermann, C., Pruijn, G. J. & Steiner, G. 2000 Analysis of the molecular composition of Ro ribonucleoprotein complexes. Identification of novel Y RNA-binding proteins. Eur. J. Biochem. 267, 2778-2789. (doi:10.1046/j.1432-1327.2000.01298.x)
30. Gabuzda, D. H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W. A. & Sodroski, J. 1992 Role of vif in replication of human immunodeficiency virus type 1 in CD4+T lymphocytes. J. Virol. 66, 6489-6495.
31. Gaddis, N. C. et al. 2004 Further investigation of simian immunodeficiency virus Vif function in human cells. J. Virol. 78, 12 041-12 046. (doi:10.1128/JVI.78.21.12041-12046.2004)
32. Gallois-Montbrun, S., Kramer, B., Swanson, C. M., Byers, H., Lynham, S., Ward, M. & Malim, M. H. 2007 Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81, 2165-2178. (doi:10.1128/JVI.02287-06)
33. Guo, F., Cen, S., Niu, M., Saadatmand, J. & Kleiman, L. 2006 Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80, 11 710-11 722. (doi:10.1128/JVI.01038-06)
34. Hache, G., Liddament, M. T. & Harris, R. S. 2005 The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280, 10 920-10 924. (doi:10.1074/jbc.M500382200)
35. Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. 2002 RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247-1253. (doi:10.1016/S1097-2765(02)00742-6)
36. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S. & Malim, M. H. 2003 DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809. (doi:10.1016/S0092-8674(03)00423-9)
37. Holmes, R. K., Koning, F. A., Bishop, K. N. & Malim, M. H. 2007 APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282, 2587-2595. (doi:10.1074/jbc.M607298200)
38. Hulme, A. E., Bogerd, H. P., Cullen, B. R. & Moran, J. V. 2007 Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390, 199-205. (doi:10.1016/j.gene.2006.08.032)
39. Iwatani, Y., Takeuchi, H., Strebel, K. & Levin, J. G. 2006 Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80, 5992-6002. (doi:10.1128/JVI.02680-05)
40. Janini, M., Rogers, M., Birx, D. R. & McCutchan, F. E. 2001 Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J. Virol. 75, 7973-7986. (doi:10.1128/JVI.75.17.7973-7986.2001)
41. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J. & Navaratnam, N. 2002 An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296. (doi:10.1006/geno.2002.6718)
42. Kanai, Y., Dohmae, N. & Hirokawa, N. 2004 Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron 43, 513-525. (doi:10.1016/j.neuron.2004.07.022)
43. Kao, S., Miyagi, E., Khan, M. A., Takeuchi, H., Opi, S., Goila-Gaur, R. & Strebel, K. 2004 Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1, 27. (doi:10.1186/1742-4690-1-27)
44. Kazazian, H. H. J. 2004 Mobile elements: drivers of genome evolution. Science 303, 1626-1632. (doi:10.1126/science.1089670)
45. Khan, M. A. et al. 2005 Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79, 5870-5874. (doi:10.1128/JVI.79.9.5870-5874.2005)
46. Khan, M. A., Goila-Gaur, R., Opi, S., Miyagi, E., Takeuchi, H., Kao, S. & Strebel, K. 2007 Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 4, 48. (doi:10.1186/1742-4690-4-48)
47. Kiebler, M. A. & Bassell, G. J. 2006 Neuronal RNA granules: movers and makers. Neuron 51, 685-690. (doi:10.1016/j.neuron.2006.08.021)
48. Klarmann, G. J., Chen, X., North, T. W. & Preston, B. D. 2003 Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J. Biol. Chem. 278, 7902-7909. (doi:10.1074/jbc.M207223200)
49. Kobayashi, M., Takaori-Kondo, A., Shindo, K., Abudu, A., Fukunaga, K. & Uchiyama, T. 2004 APOBEC3G targets specific virus species. J. Virol. 78, 8238-8244. (doi:10.1128/JVI.78.15.8238-8244.2004)
50. Kozak, S. L., Marin, M., Rose, K. M., Bystrom, C. & Kabat, D. 2006 The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281, 29 105-29 119. (doi:10.1074/jbc.M601901200)
51. Kreisberg, J. F., Yonemoto, W. & Greene, W. C. 2006 Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203, 865-870. (doi:10.1084/jem.20051856)
52. Lecossier, D., Bouchonnet, F., Clavel, F. & Hance, A. J. 2003 Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112. (doi:10.1126/science.1083338)
53. Lee, Y. N. & Bieniasz, P. D. 2007 Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 3, e10. (doi:10.1371/journal.ppat.0030010)
54. Liddament, M. T., Brown, W. L., Schumacher, A. J. & Harris, R. S. 2004 APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14, 1385-1391. (doi:10.1016/j.cub. 2004.06.050)
55. Lochelt, M. et al. 2005 The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl Acad. Sci. USA 102, 7982-7987. (doi:10.1073/pnas.0501445102)
56. Luo, K., Liu, B., Xiao, Z., Yu, Y., Yu, X., Gorelick, R. & Yu, X. F. 2004 Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78,11 841-11 852. (doi:10.1128/JVI.78.21.11841-11852.2004)
57. Luo, K., Xiao, Z., Ehrlich, E., Yu, Y., Liu, B., Zheng, S. & Yu, X. F. 2005 Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl Acad. Sci. USA 102, 11444-11449. (doi:10.1073/pnas. 0502440102)
58. Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J. & Yu, X. F. 2007 Cytidine deaminases APOBEC3G and APOBEC3F interact with HIV-1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238-7248. (doi:10.1128/JVI.02584-06)
59. Madani, N. & Kabat, D. 1998 An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72, 10 251-10 255.
60. Mahieux, R., Suspene, R., Delebecque, F., Henry, M., Schwartz, O., Wain-Hobson, S. & Vartanian, J. P. 2005 Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 86, 2489-2494. (doi:10.1099/vir.0. 80973-0)
61. Maksakova, I. A., Romanish, M. T., Gagnier, L., Dunn, C. A., van de Lagemaat, L. N. & Mager, D. L. 2006 Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line. PLoS Genet. 2, e2. (doi:10.1371/journal.pgen.0020002)
62. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L. & Trono, D. 2003 Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103. (doi:10.1038/nature01709)
63. Mangeat, B., Turelli, P., Liao, S. & Trono, D. 2004 A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279, 14 481-14 483. (doi:10.1074/jbc. C400060200)
64. Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C., Nymark-McMahon, H. & Landau, N. R. 2003 Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31. (doi:10.1016/S0092-8674(03)00515-4)
65. Marin, M., Rose, K. M., Kozak, S. L. & Kabat, D. 2003 HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403. (doi:10.1038/nm946)
66. Mbisa, J. L. et al. 2007 HIV-1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81, 7099-7110. (doi:10.1128/JVI.00272-07)
67. Mehle, A., Goncalves, J., Santa-Marta, M., McPike, M. & Gabuzda, D. 2004a Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18, 2861-2866. (doi:10.1101/gad.1249904)
68. Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M. & Gabuzda, D. 2004b Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279, 7792-7798. (doi:10.1074/jbc.M313093200)
69. Mehle, A., Thomas, E. R., Rajendran, K. S. & Gabuzda, D. 2006 A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281, 17 259-17 265. (doi:10.1074/jbc.M602413200)
70. Mehta, A., Kinter, M. T., Sherman, N. E. & Driscoll, D. M. 2000 Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol. Cell Biol. 20, 1846-1854. (doi:10.1128/MCB.20.5.1846-1854.2000)
71. Muckenfuss, H., Hamdorf, M., Held, U., Perkovic, M., Lower, J., Cichutek, K., Flory, E., Schumann, G. G. & Munk, C. 2006 APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281, 22 161-22 172. (doi:10.1074/jbc.M601716200)
72. Muramatsu, M., Sankaranand, V. S., Anant, S., Sugai, M., Kinoshita, K., Davidson, N. O. & Honjo, T. 1999 Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274, 18 470-18 476. (doi:10.1074/jbc.274.26.18470)
73. Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y. & Honjo, T. 2000 Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563. (doi:10.1016/S0092-8674(00)00078-7)
74. Navarro, F., Bollman, B., Chen, H., Konig, R., Yu, Q., Chiles, K. & Landau, N. R. 2005 Complementary function of the two catalytic domains of APOBEC3G. Virology 333, 374-386. (doi:10.1016/j.virol.2005.01.011)
75. Newman, E. N., Holmes, R. K., Craig, H. M., Klein, K. C., Lingappa, J. R., Malim, M. H. & Sheehy, A. M. 2005 Antiviral Function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166-170. (doi:10.1016/j.cub.2004.12.068)
76. OhAinle, M., Kerns, J. A., Malik, H. S. & Emerman, M. 2006 Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80, 3853-3862. (doi:10.1128/JVI.80.8.3853- 3862.2006)
77. Okazaki, I. M., Hiai, H., Kakazu, N., Yamada, S., Muramatsu, M., Kinoshita, K. & Honjo, T. 2003 Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197, 1173-1181. (doi:10.1084/jem. 20030275)
78. Okeoma, C. M., Lovsin, N., Peterlin, B. M. & Ross, S. R. 2007 APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445, 927-930. (doi:10.1038/nature05540)
79. Opi, S., Kao, S., Goila-Gaur, R., Khan, M. A., Miyagi, E., Takeuchi, H. & Strebel, K. 2007 Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81, 8236-8246. (doi:10.1128/JVI.02694-06)
80. Peng, G., Greenwell-Wild, T., Nares, S., Jin, W., Lei, K. J., Rangel, Z. G., Munson, P. J. & Wahl, S. M. 2007 Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110, 393-400. (doi:10.1182/blood-2006-10-051763)
81. Pion, M., Granelli-Piperno, A., Mangeat, B., Stalder, R., Correa, R., Steinman, R. M. & Piguet, V. 2006 APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J. Exp. Med. 203, 2887-2893. (doi:10.1084/jem.20061519)
82. Prochnow, C., Bransteitter, R., Klein, M. G., Goodman, M. F. & Chen, X. S. 2007 The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445, 447-451. (doi:10.1038/nature05492)
83. Revy, P. et al. 2000 Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102, 565-575. (doi:10.1016/S0092-8674(00)00079-9)
84. Rogozin, I. B., Basu, M. K., Jordan, I. K., Pavlov, Y. I. & Koonin, E. V. 2005 APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4, 1281-1285.
85. Rosler, C., Kock, J., Malim, M. H., Blum, H. E. & von Weizsacker, F. 2004 Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science 305, 1403. (doi:10.1126/science.1100464) author reply 1403.
86. Russell, R. A., Wiegand, H. L., Moore, M. D., Schafer, A., McClure, M. O. & Cullen, B. R. 2005 Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J. Virol. 79, 8724-8731. (doi:10.1128/JVI.79.14.8724-8731.2005)
87. Sasada, A., Takaori-Kondo, A., Shirakawa, K., Kobayashi, M., Abudu, A., Hishizawa, M., Imada, K., Tanaka, Y. & Uchiyama, T. 2005 APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2, 32. (doi:10.1186/1742-4690-2-32)
88. Sawyer, S. L., Emerman, M. & Malik, H. S. 2004 Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2, E275. (doi:10.1371/journal.pbio.0020275)
89. Schafer, A., Bogerd, H. P. & Cullen, B. R. 2004 Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328, 163-168. (doi:10.1016/j. virol.2004.08.006)
90. Schrofelbauer, B., Chen, D. & Landau, N. R. 2004 A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif ). Proc. Natl Acad. Sci. USA 101, 3927-3932. (doi:10.1073/pnas.0307132101)
91. Schrofelbauer, B., Yu, Q., Zeitlin, S. G. & Landau, N. R. 2005 Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79, 10 978-10 987. (doi:10.1128/JVI.79.17.10978-10987.2005)
92. Schrofelbauer, B., Senger, T., Manning, G. & Landau, N. R. 2006 Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80, 5984-5991.(doi:10.1128/JVI.00388-06)
93. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. 2002 Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650. (doi:10.1038/nature00939)
94. Sheehy, A. M., Gaddis, N. C. & Malim, M. H. 2003 The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407. (doi:10.1038/nm945)
95. Simon, J. H., Gaddis, N. C., Fouchier, R. A. & Malim, M. H. 1998 Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4, 1397-1400. (doi:10.1038/3987)
96. Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D. D. & Bieniasz, P. D. 2005 Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1, e6. (doi:10.1371/journal.ppat.0010006)
97. Soros, V. B., Yonemoto, W. & Greene, W. C. 2007 Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3, e15. (doi:10.1371/journal.ppat.0030015)
98. Sova, P. & Volsky, D. J. 1993 Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J. Virol. 67, 6322-6326.
99. Stenglein, M. D. & Harris, R. S. 2006 APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281, 16 837-16 841. (doi:10.1074/jbc.M602367200)
100. Stopak, K., de Noronha, C., Yonemoto, W. & Greene, W. C. 2003 HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591-601. (doi:10.1016/S1097-2765(03)00353-8)
101. Stopak, K. S., Chiu, Y. L., Kropp, J., Grant, R. M. & Greene, W. C. 2007 Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282, 3539-3546. (doi:10.1074/jbc.M610138200)
102. Suspene, R., Guetard, D., Henry, M., Sommer, P., Wain-Hobson, S. & Vartanian, J. P. 2005 Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl Acad. Sci. USA 102, 8321-8326. (doi:10.1073/pnas.0408223102)
103. Suspene, R., Rusniok, C., Vartanian, J. P. & Wain-Hobson, S. 2006 Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 34, 4677-4684. (doi:10.1093/nar/gkl555)
104. Svarovskaia, E. S., Xu, H., Mbisa, J. L., Barr, R., Gorelick, R. J., Ono, A., Freed, E. O., Hu, W. S. & Pathak, V. K. 2004 Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279, 35 822-35 828. (doi:10.1074/jbc.M405761200)
105. Teng, B., Burant, C. F. & Davidson, N. O. 1993 Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260, 1816-1819. (doi:10.1126/science.8511591)
106. Thielen, B. K., Klein, K. C., Walker, L. W., Rieck, M., Buckner, J. H., Tomblingson, G. W. & Lingappa, J. R. 2007 T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog. 3, 1320-1334. (doi:10.1371/journal.ppat.0030135)
107. Turelli, P., Mangeat, B., Jost, S., Vianin, S. & Trono, D. 2004a Inhibition of hepatitis B virus replication by APOBEC3G. Science 303, 1829. (doi:10.1126/science.1092066)
108. Turelli, P., Vianin, S. & Trono, D. 2004b The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J. Biol. Chem. 279,43 371-43 373.(doi:10.1074/jbc.C400334200)
109. Villace, P., Marion, R. M. & Ortin, J. 2004 The composition of Staufen-containing RNA granules from human cells indicates their role in the regulated transport and translation of messenger RNAs. Nucleic Acids Res. 32, 2411-2420. (doi:10.1093/nar/gkh552)
110. von Schwedler, U., Song, J., Aiken, C. & Trono, D. 1993 Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67, 4945-4955.
111. Wichroski, M. J., Ichiyama, K. & Rana, T. M. 2005 Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280, 8387-8396. (doi:10.1074/jbc.M408048200)
112. Wichroski, M. J., Robb, G. B. & Rana, T. M. 2006 Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2, e41. (doi:10.1371/journal.ppat.0020041)
113. Wiegand, H. L., Doehle, B. P., Bogerd, H. P. & Cullen, B. R. 2004 A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23, 2451-2458. (doi:10.1038/sj.emboj. 7600246)
114. Xiao, Z., Ehrlich, E., Yu, Y., Luo, K., Wang, T., Tian, C. & Yu, X. F. 2006 Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349, 290-299. (doi:10.1016/j.virol.2006.02.002)
115. Xu, H., Svarovskaia, E. S., Barr, R., Zhang, Y., Khan, M. A., Strebel, K. & Pathak, V. K. 2004 A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl Acad. Sci. USA 101, 5652-5657. (doi:10.1073/pnas.0400830101)
116. Xu, H., Chertova, E., Chen, J., Ott, D. E., Roser, J. D., Hu, W. S. & Pathak, V. K. 2007 Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360, 247-256. (doi:10.1016/j.virol.2006.10.036)
117. Yamanaka, S., Balestra, M. E., Ferrell, L. D., Fan, J., Arnold, K. S., Taylor, S., Taylor, J. M. & Innerarity, T. L. 1995 Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc. Natl Acad. Sci. USA 92, 8483-8487. (doi:10.1073/pnas.92.18.8483)
118. Yang, B., Chen, K., Zhang, C., Huang, S. & Zhang, H. 2007a Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282, 11 667-11 675. (doi:10.1074/jbc. M606864200)
119. Yang, Y., Guo, F., Cen, S. & Kleiman, L. 2007b Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365, 92-100. (doi:10.1016/j.virol.2007.03.022)
120. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P. & Yu, X. F. 2003 Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060. (doi:10.1126/science.1089591)
121. Yu, Q., Chen, D., Konig, R., Mariani, R., Unutmaz, D. & Landau, N. R. 2004a APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279, 53 379-53 386. (doi:10.1074/jbc.M408802200)
122. Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J. M. & Landau, N. R. 2004b Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442. (doi:10.1038/nsmb758)
123. Yu, Y., Xiao, Z., Ehrlich, E. S., Yu, X. & Yu, X. F. 2004c Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18, 2867-2872. (doi:10.1101/gad.1250204)
124. Zennou, V., Perez-Caballero, D., Gottlinger, H. & Bieniasz, P. D. 2004 APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78, 12 058-12 061. (doi:10.1128/JVI.78.21.12058-12061. 2004)
125. Zhang, J. & Webb, D. M. 2004 Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet. 13, 1785-1791. (doi:10.1093/hmg/ddh183)
126. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C. & Gao, L. 2003 The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98. (doi:10.1038/ nature01707)